| Esther Nkwanyuo, PMHNP | |
|
1111 W Adoue St, Alvin, TX 77511-2718 | |
| (281) 824-1480 | |
| Not Available |
| Full Name | Esther Nkwanyuo |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Psychiatric/mental Health |
| Location | 1111 W Adoue St, Alvin, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053083428 | NPI | - | NPPES |
| 1053083428 | Other | TX | OTHER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 754745 (Texas) | Secondary |
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | 1093551 (Texas) | Primary |
| Entity Name | Stephen F Austin Community Health Center,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578730818 PECOS PAC ID: 6204977127 Enrollment ID: O20100113000886 |
News Archive
CML HealthCare Income Fund (the "Fund" or "CML HealthCare"), (TSX: CLC.UN) today announced that its operating subsidiary, CML HealthCare Inc. ("CML") has entered into definitive agreements to acquire two medical imaging operations comprising six centers located in the Northeast United States.
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.
pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).
Adverse events for patients being treated for heart attack and heart failure have declined, according to a new study published in the January 23 issue of the New England Journal of Medicine. However, the analysis funded by the Agency for Healthcare Research and Quality found that there has not been a significant decrease in adverse events for patients being treated for pneumonia and those who are recovering from surgery.
› Verified 7 days ago
| Entity Name | Wholeness Healthcare Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497443865 PECOS PAC ID: 8820454382 Enrollment ID: O20230525002350 |
News Archive
CML HealthCare Income Fund (the "Fund" or "CML HealthCare"), (TSX: CLC.UN) today announced that its operating subsidiary, CML HealthCare Inc. ("CML") has entered into definitive agreements to acquire two medical imaging operations comprising six centers located in the Northeast United States.
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.
pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).
Adverse events for patients being treated for heart attack and heart failure have declined, according to a new study published in the January 23 issue of the New England Journal of Medicine. However, the analysis funded by the Agency for Healthcare Research and Quality found that there has not been a significant decrease in adverse events for patients being treated for pneumonia and those who are recovering from surgery.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Esther Nkwanyuo, PMHNP 1111 W Adoue St, Alvin, TX 77511-2718 Ph: () - | Esther Nkwanyuo, PMHNP 1111 W Adoue St, Alvin, TX 77511-2718 Ph: (281) 824-1480 |
News Archive
CML HealthCare Income Fund (the "Fund" or "CML HealthCare"), (TSX: CLC.UN) today announced that its operating subsidiary, CML HealthCare Inc. ("CML") has entered into definitive agreements to acquire two medical imaging operations comprising six centers located in the Northeast United States.
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.
pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).
Adverse events for patients being treated for heart attack and heart failure have declined, according to a new study published in the January 23 issue of the New England Journal of Medicine. However, the analysis funded by the Agency for Healthcare Research and Quality found that there has not been a significant decrease in adverse events for patients being treated for pneumonia and those who are recovering from surgery.
› Verified 7 days ago
Elisa Mone't Montgomery, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1111 W Adoue St, Alvin, TX 77511 Phone: 281-824-1480 | |
Beverly J Howard, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1111 W Adoue St, Alvin, TX 77511 Phone: 281-824-1480 Fax: 281-220-6407 | |
Mrs. Courtney Nicole Simmons-matthews, APRN, CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1111 W Adoue St, Alvin, TX 77511 Phone: 281-824-1480 | |
Amee Hugg Stoneman, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1111 W Adoue St, Alvin, TX 77511 Phone: 281-824-1480 | |
Ms. Jan Slovacek, F.N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3128 S Highway 35, Alvin, TX 77511 Phone: 281-886-8964 | |
Tison Latoi Price Hudson, MSN, RN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3128 Texas 35 S, Alvin, TX 77511 Phone: 281-886-8964 | |
Ajikele Nwankwo, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1111 W Adoue St, Alvin, TX 77511 Phone: 281-824-1480 |